These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18236140)

  • 41. Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies.
    Penza P; Campanella A; Martini A; Melli G; Lombardi R; Camozzi F; Devigili G; Lauria G
    J Peripher Nerv Syst; 2008 Dec; 13(4):283-8. PubMed ID: 19192068
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transdermal buprenorphine combined with spinal morphine and naropine for pain relief in chronic peripheral vasculopathy.
    Aurilio B; Pace MC; Passavanti MB
    Minerva Anestesiol; 2005; 71(7-8):445-9. PubMed ID: 16012418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R; Kayser H; Sittl R
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Electrically-assisted transdermal delivery of buprenorphine.
    Bose S; Ravis WR; Lin YJ; Zhang L; Hofmann GA; Banga AK
    J Control Release; 2001 Jun; 73(2-3):197-203. PubMed ID: 11516497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Allergic contact dermatitis from transdermal buprenorphine.
    Vander Hulst K; Parera Amer E; Jacobs C; Dewulf V; Baeck M; Pujol Vallverdú RM; Giménez-Arnau A; Tennstedt D; Goossens A
    Contact Dermatitis; 2008 Dec; 59(6):366-9. PubMed ID: 19076888
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The transdermal 7-day buprenorphine patch--an effective and safe treatment option, if tramadol or tilidate/naloxone is insufficient. Results of a non-interventional study].
    Schutter U; Ritzdorf I; Heckes B
    MMW Fortschr Med; 2010 Jul; 152 Suppl 2():62-9. PubMed ID: 21591321
    [TBL] [Abstract][Full Text] [Related]  

  • 50. No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery.
    Okkerse P; Alvarez-Jimenez R; Hay JL; Tehim A; Kumar R; de Kam ML; Groeneveld GJ
    Eur J Pain; 2017 Mar; 21(3):494-506. PubMed ID: 27651026
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Application of a buprenorphine transdermal patch for the perioperative analgesia in patients who underwent simple lumbar discectomy.
    Tang J; Fan J; Yao Y; Cai W; Yin G; Zhou W
    Medicine (Baltimore); 2017 May; 96(20):e6844. PubMed ID: 28514299
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Sorge J; Sittl R
    Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat.
    Tejwani GA; Rattan AK
    Anesth Analg; 2002 Jun; 94(6):1542-6, table of contents. PubMed ID: 12032023
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain.
    Ripa SR; McCarberg BH; Munera C; Wen W; Landau CJ
    Expert Opin Pharmacother; 2012 Jun; 13(9):1229-41. PubMed ID: 22409388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of analgesic effect and absorption of buprenorphine after buccal administration in cats with oral disease.
    Stathopoulou TR; Kouki M; Pypendop BH; Johnston A; Papadimitriou S; Pelligand L
    J Feline Med Surg; 2018 Aug; 20(8):704-710. PubMed ID: 28895776
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of Buprenorphine and Sustained-release Buprenorphine in Common Marmosets (
    Fitz CB; Goodroe AE; Moody DE; Fang WB; Capuano SV
    J Am Assoc Lab Anim Sci; 2021 Mar; 60(2):188-194. PubMed ID: 33375952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel depots of buprenorphine prodrugs have a long-acting antinociceptive effect.
    Liu KS; Tzeng JI; Chen YW; Huang KL; Kuei CH; Wang JJ
    Anesth Analg; 2006 May; 102(5):1445-51. PubMed ID: 16632824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of low-dose and high-dose buprenorphine in cats after rectal administration of different formulations.
    Schroers M; Meyer-Lindenberg A; Reese S; Dobenecker B; Pieper K
    J Feline Med Surg; 2019 Oct; 21(10):938-943. PubMed ID: 30427272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Allergic contact dermatitis due to transdermal buprenorphine.
    Pérez-Pérez L; Cabanillas M; Loureiro M; Fernández-Redondo V; Labandeira J; Toribio J
    Contact Dermatitis; 2008 May; 58(5):310-2. PubMed ID: 18416765
    [No Abstract]   [Full Text] [Related]  

  • 60. Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder.
    Laffont CM; Gomeni R; Heidbreder C; Jones JP; Nasser AF
    J Clin Pharmacol; 2016 Jul; 56(7):806-15. PubMed ID: 26479717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.